Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H21FN2O4 |
Molecular Weight | 360.3794 |
Optical Activity | ( - ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CCC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCC(O)CC4
InChI
InChIKey=JYJTVFIEFKZWCJ-JTQLQIEISA-N
InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)/t10-/m0/s1
Molecular Formula | C19H21FN2O4 |
Molecular Weight | 360.3794 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Levonadifloxacin is the S-(-) isomer of the benzoquinolizine fluoroquinolone nadifloxacin and is two- to four-fold more active than the racemic mixture. Levonadifloxacin is a potent antibacterial agent against Gram-positive bacteria especially against methicillin resistance Staphylococcus aureus. It also possesses potent bactericidal activity against other resistant variants like quinolone-resistant Staphylococcus aureus, vancomycin and glycopeptide intermediate Staphylococcus aureus and vancomycin resistant Staphylococcus aureus. Intravenous dosage form developed to treat complicated skin and skin structure infections and has recently completed Phase III studies in India and Phase I studies in USA.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. | 2003 Nov |
|
In vitro activity of the new quinolone WCK 771 against staphylococci. | 2004 Sep |
|
Validated chiral high-performance liquid chromatography method for a novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771. | 2006 Mar 3 |
|
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. | 2006 Nov |
|
Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. | 2006 Oct |
|
Simple liquid chromatography-tandem mass spectrometry method for determination of novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771 in human serum. | 2007 Feb 1 |
|
Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. | 2018 Mar |
|
In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms. | 2018 Nov |
|
Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone. | 2019 Jan |
|
Identification of metabolites of novel Anti-MRSA fluoroquinolone WCK 771 in mouse, rat, rabbit, dog, monkey and human urine using liquid chromatography tandem mass spectrometry. | 2019 Jul |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:05:27 UTC 2023
by
admin
on
Fri Dec 15 17:05:27 UTC 2023
|
Record UNII |
8WHH66L098
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C795
Created by
admin on Fri Dec 15 17:05:27 UTC 2023 , Edited by admin on Fri Dec 15 17:05:27 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9850038
Created by
admin on Fri Dec 15 17:05:27 UTC 2023 , Edited by admin on Fri Dec 15 17:05:27 UTC 2023
|
PRIMARY | |||
|
C83879
Created by
admin on Fri Dec 15 17:05:27 UTC 2023 , Edited by admin on Fri Dec 15 17:05:27 UTC 2023
|
PRIMARY | |||
|
8WHH66L098
Created by
admin on Fri Dec 15 17:05:27 UTC 2023 , Edited by admin on Fri Dec 15 17:05:27 UTC 2023
|
PRIMARY | |||
|
DTXSID70165599
Created by
admin on Fri Dec 15 17:05:27 UTC 2023 , Edited by admin on Fri Dec 15 17:05:27 UTC 2023
|
PRIMARY | |||
|
300000034280
Created by
admin on Fri Dec 15 17:05:27 UTC 2023 , Edited by admin on Fri Dec 15 17:05:27 UTC 2023
|
PRIMARY | |||
|
8649
Created by
admin on Fri Dec 15 17:05:27 UTC 2023 , Edited by admin on Fri Dec 15 17:05:27 UTC 2023
|
PRIMARY | |||
|
154357-42-3
Created by
admin on Fri Dec 15 17:05:27 UTC 2023 , Edited by admin on Fri Dec 15 17:05:27 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
RACEMATE -> ENANTIOMER |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|